Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott(Brigham and Women's Hospital), Marc S. Sabatine(Brigham and Women's Hospital), Julia Kuder(Brigham and Women's Hospital), Deepak L. Bhatt(Mount Sinai Hospital), Michael G. Silverman(Harvard University), Thomas A. Zelniker(Medical University of Vienna), Christian T. Ruff(Brigham and Women's Hospital), Martin Fredriksson(Linköping University), John Wilding(University of Liverpool), Avivit Cahn(Hebrew University of Jerusalem), Peter A. Johansson(AstraZeneca (Sweden)), Darren K. McGuire(Parkland Health & Hospital System), Lawrence A. Leiter(St. Michael's Hospital), Ofri Mosenzon(Hebrew University of Jerusalem), Sabina A. Murphy(Brigham and Women's Hospital), Marc P. Bonaca(The Medical Center of Aurora), Anna-Maria Langkilde(AstraZeneca (Finland)), Eri Kato(Kyoto University Hospital), Itamar Raz(Hebrew University of Jerusalem), Ingrid Gause‐Nilsson(Thrombolysis in Myocardial Infarction Study Group)
Cited by 6,287
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k